PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16837557-7	2006	Chronic nicotine treatment led to a small decrease in alpha3/alpha6beta2* nAChR subtypes.	Nicotine	8-16	immunoglobulin kappa variable 2D-28	Homo sapiens	54-72	
16837557-8	2006	The decline in alpha3/alpha6beta2* subtypes, defined using alpha-conotoxinMII-sensitive (125)I-epibatidine or [(125)I]A85380 binding, was significantly smaller in striatum of nicotine-treated lesioned monkeys compared with unlesioned monkeys.	Nicotine	175-183	immunoglobulin kappa variable 2D-28	Homo sapiens	15-33	
16837557-10	2006	These data suggest that there are at least two striatal alpha3/alpha6beta2* subtypes that are differentially affected by chronic nicotine treatment in lesioned animals.	Nicotine	129-137	immunoglobulin kappa variable 2D-28	Homo sapiens	56-74	
16837557-11	2006	In addition, the results showing an improvement in striatal alpha4beta2* and select alpha3/alpha6beta2* nAChR subtypes, combined with previous work, demonstrate that chronic nicotine treatment restores and/or protects against the loss of multiple molecular markers after nigrostriatal damage.	Nicotine	174-182	immunoglobulin kappa variable 2D-28	Homo sapiens	84-102